Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

• Published in: Clinical infectious diseases Vol. 63; no. 11; pp. 1479 - 1481
• Main Authors: Grebely, Jason, Dore, Gregory J., Zeuzem, Stefan, Aspinall, Richard J., Fox, Raymond, Han, Lingling, McNally, John, Osinusi, Anu, Brainard, Diana M., Subramanian, G. Mani, Natha, Macky, Foster, Graham R., Mangia, Alessandra, Sulkowski, Mark, Feld, Jordan J.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01-12-2016
• Subjects: Adult; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; BRIEF REPORTS; Carbamates - administration & dosage; Carbamates - adverse effects; Carbamates - therapeutic use; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C virus; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - genetics; Hepatitis C, Chronic - virology; Heterocyclic Compounds, 4 or More Rings - administration & dosage; Heterocyclic Compounds, 4 or More Rings - adverse effects; Heterocyclic Compounds, 4 or More Rings - therapeutic use; Humans; Liver Cirrhosis - drug therapy; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Prescription drugs; Ribavirin - therapeutic use; Safety; Sofosbuvir - administration & dosage; Sofosbuvir - adverse effects; Sofosbuvir - therapeutic use; Substance abuse treatment; Sustained Virologic Response; Treatment Outcome; sofosbuvir; OST; HCV; velpatasvir; PWID
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1093/cid/ciw579

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.